비소세포성폐암의 방사선치료 성적

Treatment of Unresectale Non-Small-Cell Lung Cancer with Curative Radiotherapy

  • 김일한 (서울대학교 의과대학 방사선과학교실) ;
  • 하성환 (서울대학교 의과대학 방사선과학교실) ;
  • 박찬일 (서울대학교 의과대학 방사선과학교실) ;
  • 심영수 (서울대학교 의과대학 내과학교실) ;
  • 김노경 (서울대학교 의과대학 내과학교실) ;
  • 김건열 (서울대학교 의과대학 내과학교실) ;
  • 한용철 (서울대학교 의과대학 내과학교실)
  • Kim Il Han (Department of Radiology, College of Medicine, Seoul National University) ;
  • Ha Sung Whan (Department of Radiology, College of Medicine, Seoul National University) ;
  • Park Charn Il (Department of Radiology, College of Medicine, Seoul National University) ;
  • Shim Young Soo (Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Kim Noe Kyeong (Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Kim Keun Youl (Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Han Yong Chol (Department of Internal Medicine, College of Medicine, Seoul National University)
  • 발행 : 1984.12.01

초록

From 1979 to 1982, 80 patients with unresectable non-small-cell lung cancer without metastasis were treated with high-dose radiotherapy to the primary and to regional lymph nodes with or without supraclavicular lymphatics in the Department of Therapeutic Radiology, Seoul National University Hospital. Of these, 56 patients$(70\%)$ were completely evaluable, and 59 patients$(74\%)$ had squamous cell carcinoma, 13a large cell undifferentiated carcinoma and 831 adenocarcinoma. 21 patients$(26\%)$ had Stage II and 59 patients$(74\%)$ had Stage III. The complete and partial response rate in the high-dose$(\approx\;6,000\;rad)$ radiotherapy was $70\%\;with\;19\%$ complete response. 69 patients$(86\%)$ failed in the treatment, by the failure pattern, $64\%$ had local failure alone, $35\%$ had local failure and distant metastasis and $1\%$ had distant metastasis alone. The failure rate in the thorax were $76\%$ in squamous cell carcinoma, $40\%$in adenocarcinoma and $20\%$ in large cell undifferentiated carcinoma Preliminary result shows that actuarial survival at 1, 2 and 3 years were $56\%,\;26\%\;and\;20\%$ in overall patients and $64\%,\;37\%\;and\;21\%\;in\;Stage\;II\;and\;54\%1,\;21\%\;and\;18\%$ in Stage III, respectively. Overall median survival was 14 months; 17 months in Stage II and 13 months in Stage m. 8 patients$(10\%)$ have lived a minimum of 2 years with no evidence of disease. There was no fatal complication confirmed to be induced by radiotherapy, so definitive high-dose radiotherapy was tolerated well without major problems and resulted in good local control and survival.

키워드